Krebs Biochemicals & Industries

79.20
+1.56
(2.01%)
Market Cap
170.76 Cr
EPS
-9.16
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
129.07
52 Week Low
61.00
PB Ratio
-1.34
Debt to Equity
2.83
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,743.70
#1 4,18,372.04
35.48
#1 49,887.20
12.06
#1 9,648
13.77
55.14
5,987.00
1,58,936.04
75.63
8,184.00
0.89
1,600
#1 64.53
57.37
1,520.00
1,22,757.47
24.47
26,520.70
14.17
4,155
47.38
57.37
3,241.60
1,09,710.47
59.14
10,785.70
11.59
1,656
13.54
56.98
2,599.90
1,07,266.29
52.21
10,615.60
19.57
1,942
-16.38
65.89
1,172.80
97,864.93
#1 18.29
28,905.40
12.36
5,578
1.69
56.93
2,040.10
93,138.92
31.97
20,141.50
#1 19.94
1,936
38.82
50.80
849.25
85,454.42
18.76
19,831.50
13.82
3,831
29.92
42.63
1,200.10
69,702.00
19.78
29,559.20
17.55
3,169
-10.04
60.21
31,020.00
65,915.33
49.20
6,097.20
10.80
1,201
16.01
57.97
Growth Rate
Revenue Growth
-3.60 %
Net Income Growth
-20.24 %
Cash Flow Change
109.31 %
ROE
-33.35 %
ROCE
-25.04 %
EBITDA Margin (Avg.)
-43.42 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
0
2
3
34
48
34
54
61
53
51
50
Expenses
5
14
11
41
58
52
71
94
68
59
62
EBITDA
-5
-11
-8
-7
-10
-18
-17
-33
-15
-8
-12
Operating Profit %
0 %
-962 %
-246 %
-22 %
-21 %
-56 %
-33 %
-57 %
-30 %
-17 %
-26 %
Depreciation
2
5
4
4
4
5
5
6
7
7
7
Interest
4
1
4
5
6
6
6
5
3
5
6
Profit Before Tax
-8
-16
-16
-18
-20
-29
-28
-45
-25
-20
-25
Tax
0
0
0
0
0
0
0
0
0
0
0
Net Profit
-8
-16
-16
-18
-20
-29
-28
-45
-25
-20
-25
EPS in ₹
-8.24
-12.49
-11.68
-12.97
-12.83
-17.90
-14.37
-20.81
-11.30
-9.16
-11.40

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
108
116
122
126
142
134
159
190
175
178
Fixed Assets
58
93
102
101
101
105
118
139
147
150
Current Assets
15
9
13
17
31
19
21
36
16
17
Capital Work in Progress
0
11
4
4
4
4
12
8
4
2
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
50
13
16
21
38
24
29
43
24
26
Total Liabilities
108
116
122
126
142
134
159
190
175
178
Current Liabilities
29
30
32
42
55
43
48
78
49
62
Non Current Liabilities
61
74
89
101
102
116
154
187
225
236
Total Equity
18
13
2
-18
-14
-25
-43
-75
-100
-119
Reserve & Surplus
-14
-4
-12
-32
-31
-43
-67
-97
-121
-141
Share Capital
10
13
14
14
17
18
20
22
22
22

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
6
-6
-0
0
17
-17
1
-1
0
0
Investing Activities
-3
-4
-5
-3
-4
-10
-23
-23
-13
-8
Operating Activities
-45
-15
-11
-6
4
-36
-15
-17
-25
2
Financing Activities
54
13
16
9
17
29
38
40
37
6

Share Holding

% Holding
Mar 2021
Apr 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
70.05 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
72.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.01 %
0.50 %
0.50 %
0.50 %
0.50 %
0.50 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
19.03 %
17.32 %
18.26 %
19.34 %
18.96 %
19.24 %
19.26 %
18.77 %
18.67 %
18.57 %
18.54 %
18.80 %
19.00 %
20.11 %
19.97 %
19.80 %
20.02 %
20.42 %
Others
10.92 %
9.94 %
9.00 %
7.91 %
8.30 %
8.01 %
8.00 %
8.48 %
8.59 %
8.68 %
8.71 %
8.45 %
8.25 %
6.65 %
6.79 %
6.96 %
6.74 %
6.34 %
No of Share Holders
0
6,400
6,400
7,096
8,571
8,166
9,531
9,533
9,650
9,294
9,393
9,030
8,990
8,909
8,848
9,425
9,091
8,798

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Announcement under Regulation 30 (LODR)-CessationMar 24, 2025
Closure of Trading WindowMar 18, 2025
Announcement under Regulation 30 (LODR)-CessationMar 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 26, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2025
Announcement under Regulation 30 (LODR)-CessationFeb 11, 2025
Order Received From Andhra Pradesh Pollution Control BoardFeb 10, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Reconstitution Of Various Committees Of The Board Of CompanyFeb 04, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 04, 2025
Integrated Filing (Financial)Feb 04, 2025
Financial Result For The Quarter Ended 31.12.2024Feb 04, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 04, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Integrated Filing (Governance)Jan 13, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 02, 2025
Announcement under Regulation 30 (LODR)-CessationDec 31, 2024
Reply To Clarification Sought On Price MovementNov 28, 2024
Clarification sought from Krebs Biochemicals & Industries LtdNov 28, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2024
Financial Result For The Quarter And Half Year Ended 30.09.2024Nov 11, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 11, 2024
Board Meeting Intimation for Intimation Of Board MeetingOct 28, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 04, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 28, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 27, 2024
Closure of Trading WindowSep 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2024
Notice Of 32Nd Annual General Meeting Of The CompanySep 02, 2024
Reg. 34 (1) Annual Report.Sep 02, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2024
Financial Results For The Quarter Ended 30.06.2024Aug 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 07.08.2024Aug 07, 2024
Board Meeting Intimation for Intimation Of Board Meeting Under Reg 29 Of The SEBI (LODR) Regulations, 2015Jul 19, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 09, 2024
Closure of Trading WindowJun 21, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2024
Appointment of Company Secretary and Compliance OfficerMay 21, 2024
Financial Results For The Year Ended 31.03.2024May 21, 2024
Board Meeting Outcome for Outcome Of Board MeetingMay 21, 2024
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday, May 21, 2024, Inter-Alia, To Consider And Adopt The Audited Financial Results For The 4Th Quarter And Financial Year Ended 31St March, 2024.May 08, 2024
Submission Of Certificate Under Reg. 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31.03.2024Apr 22, 2024
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerApr 15, 2024

Technical Indicators

RSI(14)
Neutral
52.96
ATR(14)
Volatile
5.36
STOCH(9,6)
Neutral
70.56
STOCH RSI(14)
Overbought
93.58
MACD(12,26)
Bullish
1.38
ADX(14)
Weak Trend
21.72
UO(9)
Bearish
43.32
ROC(12)
Uptrend And Accelerating
16.98
WillR(14)
Neutral
-31.22